The record
| Class | regenerative |
|---|---|
| Also known as | Body Protection Compound 157, Bepecin, PL 14736, PL-10 |
| Chain length | - |
| Molecular weight | 1,419.5 Da |
| Half-life | Not well characterized |
| Route | SC, oral (stable in stomach) |
| Studied for | - |
| Research use | Wound healing models; Tendon/ligament repair; GI protection studies |
| What has been shown | Accelerated wound healing; Tendon/ligament repair; GI ulcer healing; Reduced inflammation |
| How it works | Synthetic peptide based on body protection compound from gastric juice. Pleiotropic effects: (1) Upregulates growth factor receptors, (2) Promotes angiogenesis via VEGF/NO, (3) Activates FAK-paxillin pathway, (4) Modulates inflammatory response, (5) Protects endothelium, (6) Interacts with dopaminergic and serotonergic systems. Stable in gastric acid. |
| Patent status | University of Zagreb patents |
| Regulatory status | Research only |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Joint / Tendon Healing (affection, 70%)
- Muscle Recovery (affection, 51%)
- Wound Healing / Tissue Repair (affection, 45%)
- Skin Regeneration / Aesthetic Healing (affection, 47%)
- Nerve Support / Neuro-repair Environment (affection, 48%)
- GI Barrier / Gut Integrity (affection, 86%)
- GI Inflammation Modulation (affection, 60%)
- Neuroprotection Signaling (affection, 59%)
- Inflammation Modulation (affection, 38%)
- Bone Health / Remodeling Support (affection, 57%)
- Anti-fibrotic Signaling Environment (affection, 48%)
- Alzheimer's disease (illness, 30%)
- Androgenetic alopecia (illness, 40%)
- Anti-biofilm treatment (illness, 30%)
- Antimicrobial applications (illness, 30%)
- Cancer immunotherapy adjuvant (illness, 30%)
- Cardiac repair (illness, 45%)
- Cardiac repair after myocardial infarction (illness, 40%)
- Chronic inflammatory conditions (illness, 30%)
- Corneal injuries/dry eye (illness, 45%)
- COVID-19 (illness, 30%)
- Diabetic neuropathy (illness, 30%)
- Duchenne muscular dystrophy (illness, 30%)
- Hair follicle regeneration (illness, 40%)
- Hepatitis B/C treatment (illness, 30%)
- Immunomodulation (illness, 30%)
- Muscle wasting conditions (illness, 36%)
- Neuromuscular diseases (illness, 30%)
- Neuropathic pain (illness, 30%)
- Neurotrophic keratopathy (illness, 45%)
- Post-injury muscle recovery (illness, 40%)
- Post-stroke recovery (illness, 40%)
- Sarcoidosis-associated small fiber neuropathy (illness, 30%)
- Scar reduction (illness, 40%)
- Sepsis treatment (illness, 30%)
- Sepsis/endotoxemia protection (illness, 30%)
- Soft tissue repair (illness, 40%)
- Vaccine adjuvant (illness, 30%)
- Vascular dementia (illness, 30%)
- Wound healing (illness, 38%)
- Wound healing enhancement (illness, 40%)
- Pain (symptom, 50%)
- Joint pain or stiffness (symptom, 50%)
- Slow healing of an injury (symptom, 75%)
- Muscle loss or weakness (symptom, 33%)
- Gut trouble (symptom, 50%)
- Frequent infections (symptom, 50%)